Ignite Creation Date:
2025-12-24 @ 11:33 PM
Ignite Modification Date:
2026-02-12 @ 4:18 AM
Study NCT ID:
NCT02407756
Status:
COMPLETED
Last Update Posted:
2020-11-27
First Post:
2015-03-31
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)
Sponsor:
Regeneron Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-03-31
Start Date Type:
ACTUAL
Primary Completion Date:
2016-03-31
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-03-31
Completion Date Type:
ACTUAL
First Submit Date:
2015-03-31
First Submit QC Date:
None
Study First Post Date:
2015-04-03
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-09-10
Results First Submit QC Date:
None
Results First Post Date:
2020-10-05
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-11-24
Last Update Post Date:
2020-11-27
Last Update Post Date Type:
ACTUAL